For more than 75 years, Grifols has been improving the health and well-being of people. Our patients are our priority, and our commitment to their health has enabled us to become a global healthcare leader with presence in more than 100 countries. The Grifols legacy embodies a spirit of innovation and a forward thinking approach and establish us as an international benchmark in the plasma collection market, the production of plasma derived therapies and transfusion medicine.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

DEALS THIS WEEK: GRIFOLS, CELLESCE, ARENA PHARMACEUTICALS

pharmaceutical-technology | April 21, 2017

news image

Spanish pharmaceutical company Grifols has raised €1bn ($1.06bn) through a public offering of bonds. Due 1 May 2025, the unsecured bonds carry a coupon rate of 3.2%.The offering is intended to refinance the bonds issued by the company in March 2014....

Read More

GRIFOLS DONATIONS OF BLOOD CLOTTING FACTOR HELPING PEOPLE WITH HEMOPHILIA GLOBALLY

pharmiweb | April 15, 2019

news image

Grifols, one of the world's three top providers of plasma-derived medicines to treat life-threatening diseases, today announced that its long-term global initiative to providing treatment to people with hemophilia in developing regions has surpassed 100 million international units (IUs) in donated blood clotting factor, a protein in blood that controls bleeding. Grifols is working to enhance the lives of the roughly 100,000 people around the world who have hemophilia but receive little or no...

Read More

GRIFOLS TO ACQUIRE MONTREAL-BASED PLASMA FRACTIONATION FACILITY AND TWO PURIFICATION FACILITIES FOR US$460 MILLION

Grifols, Green Cross Corporation | July 21, 2020

news image

Grifols, a global healthcare company and one of world's top producers of plasma-derived medicines, today announced it has executed purchase arrangements with the South Korean-based GC Pharma (Group) whereby Grifols will acquire the Montreal-based plasma fractionation facility and two purification facilities, along with 11 U.S.-based plasma collection centers for a total amount of US$460 million. The transaction is part of Grifols' sustainable global growth strategy to expa...

Read More

GROUND-BREAKING COLLABORATION TO OFFER NEW HEART DISEASE DRUG TO NHS PATIENTS

Pharmacy Business | January 14, 2020

news image

The government on Monday announced a collaboration with Novartis to launch a clinical trial for ‘yet to be approved’ drug inclisiran. The drug could benefit thousands of patients at risk of heart disease in coming years. The ground-breaking collaboration includes Novartis, NHS England and the National Institute for Health Research (NIHR) and Oxford University. The Department of Health and Social Care (DHSC) expects this to position the UK as a world-leading destination to develop cut...

Read More
news image

DEALS THIS WEEK: GRIFOLS, CELLESCE, ARENA PHARMACEUTICALS

pharmaceutical-technology | April 21, 2017

Spanish pharmaceutical company Grifols has raised €1bn ($1.06bn) through a public offering of bonds. Due 1 May 2025, the unsecured bonds carry a coupon rate of 3.2%.The offering is intended to refinance the bonds issued by the company in March 2014....

Read More
news image

GRIFOLS DONATIONS OF BLOOD CLOTTING FACTOR HELPING PEOPLE WITH HEMOPHILIA GLOBALLY

pharmiweb | April 15, 2019

Grifols, one of the world's three top providers of plasma-derived medicines to treat life-threatening diseases, today announced that its long-term global initiative to providing treatment to people with hemophilia in developing regions has surpassed 100 million international units (IUs) in donated blood clotting factor, a protein in blood that controls bleeding. Grifols is working to enhance the lives of the roughly 100,000 people around the world who have hemophilia but receive little or no...

Read More
news image

GRIFOLS TO ACQUIRE MONTREAL-BASED PLASMA FRACTIONATION FACILITY AND TWO PURIFICATION FACILITIES FOR US$460 MILLION

Grifols, Green Cross Corporation | July 21, 2020

Grifols, a global healthcare company and one of world's top producers of plasma-derived medicines, today announced it has executed purchase arrangements with the South Korean-based GC Pharma (Group) whereby Grifols will acquire the Montreal-based plasma fractionation facility and two purification facilities, along with 11 U.S.-based plasma collection centers for a total amount of US$460 million. The transaction is part of Grifols' sustainable global growth strategy to expa...

Read More
news image

GROUND-BREAKING COLLABORATION TO OFFER NEW HEART DISEASE DRUG TO NHS PATIENTS

Pharmacy Business | January 14, 2020

The government on Monday announced a collaboration with Novartis to launch a clinical trial for ‘yet to be approved’ drug inclisiran. The drug could benefit thousands of patients at risk of heart disease in coming years. The ground-breaking collaboration includes Novartis, NHS England and the National Institute for Health Research (NIHR) and Oxford University. The Department of Health and Social Care (DHSC) expects this to position the UK as a world-leading destination to develop cut...

Read More